Concepedia

Ikumi Nakashima

IN

3

Publications

314

Citations

3

H-Index

2008

Active since

Affiliations

Kissei Pharmaceutical (Japan)(Current)

Ikumi Nakashima is an author at Kissei Pharmaceutical (Japan) specializing in metabolic syndrome, health sciences, and diabetes.

Top concepts

Publications per year

2008–2021

3

Publications

3

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

Yoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 219 citations

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

Yoshikazu Fujimori, Kenji Katsuno, Kazuma Ojima et al. · European Journal of Pharmacology · 2009 · 70 citations

, , +9

Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia

Aiko Hasegawa, Shoji Saito, Shogo Narimatsu et al. · Clinical & Translational Immunology · 2021 · 25 citations · Full text

Rows per page

1–3 of 3